Insider Buying: Altimmune, Inc. (NASDAQ:ALT) CFO Buys $52,000.00 in Stock

Altimmune, Inc. (NASDAQ:ALT) CFO Gregory L. Weaver acquired 10,000 shares of the company’s stock in a transaction dated Thursday, March 13th. The stock was acquired at an average cost of $5.20 per share, with a total value of $52,000.00. Following the transaction, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at approximately $52,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Altimmune Price Performance

Shares of ALT stock opened at $5.92 on Monday. The firm has a market cap of $455.92 million, a P/E ratio of -3.82 and a beta of 0.87. Altimmune, Inc. has a 1-year low of $5.14 and a 1-year high of $11.16. The firm has a fifty day moving average of $6.48 and a two-hundred day moving average of $7.12.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.01. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. On average, sell-side analysts expect that Altimmune, Inc. will post -1.35 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research note on Monday, March 3rd. William Blair reaffirmed a “market perform” rating on shares of Altimmune in a research note on Friday. Finally, Stifel Nicolaus started coverage on shares of Altimmune in a research note on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.83.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ALT. Ameriprise Financial Inc. boosted its holdings in shares of Altimmune by 35.6% in the 4th quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company’s stock valued at $37,888,000 after buying an additional 1,378,854 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Altimmune by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock valued at $10,244,000 after buying an additional 74,194 shares during the period. Bellevue Group AG boosted its holdings in shares of Altimmune by 9.5% in the 4th quarter. Bellevue Group AG now owns 945,446 shares of the company’s stock valued at $6,817,000 after buying an additional 81,786 shares during the period. Northern Trust Corp boosted its holdings in shares of Altimmune by 5.7% in the 4th quarter. Northern Trust Corp now owns 665,916 shares of the company’s stock valued at $4,801,000 after buying an additional 35,918 shares during the period. Finally, Two Sigma Investments LP boosted its holdings in shares of Altimmune by 33.2% in the 4th quarter. Two Sigma Investments LP now owns 605,303 shares of the company’s stock valued at $4,364,000 after buying an additional 151,001 shares during the period. 78.05% of the stock is owned by institutional investors and hedge funds.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.